Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Income from Continuing Operations (2019 - 2025)

Allogene Therapeutics' Income from Continuing Operations history spans 7 years, with the latest figure at 41319000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 36.6% year-over-year to 41319000.0; the TTM value through Sep 2025 reached 209588000.0, up 23.65%, while the annual FY2024 figure was 257590000.0, 21.29% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 41319000.0 at Allogene Therapeutics, up from 50900000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1893000.0 in Q4 2021 and bottomed at 99092000.0 in Q1 2023.
  • The 5-year median for Income from Continuing Operations is 66443000.0 (2024), against an average of 64965789.47.
  • The largest annual shift saw Income from Continuing Operations soared 102.76% in 2021 before it crashed 5195.67% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 1893000.0 in 2021, then plummeted by 5195.67% to 96461000.0 in 2022, then grew by 18.26% to 78844000.0 in 2023, then grew by 27.02% to 57544000.0 in 2024, then rose by 28.2% to 41319000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Income from Continuing Operations are 41319000.0 (Q3 2025), 50900000.0 (Q2 2025), and 59825000.0 (Q1 2025).